Form 4: Xencor Inc. SVP, General Counsel Celia Eckert Reports Acquisition of Shares and Stock Options

Celia Eckert, SVP, General Counsel of Xencor Inc., reports the acquisition of common stock and stock options, including shares from the Employee Stock Purchase Plan and a grant of restricted stock units.

Summary

• On March 4, 2025, Celia Eckert, SVP, General Counsel of Xencor Inc., filed a Form 4 detailing changes in beneficial ownership.
• Eckert acquired 21,949 shares of common stock, including restricted stock units vesting over three years and shares from the Employee Stock Purchase Plan.
• She also acquired 65,847 stock options with an exercise price of $14.15, vesting over four years from March 4, 2025.
• The report also corrects a clerical error in previous filings, adding 597 shares previously omitted.
• Following the reported transactions, Eckert beneficially owns 69,247 shares of common stock and 65,847 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The filing primarily reflects routine transactions and corrections. The acquisition of shares through the employee stock purchase plan and the vesting of stock options suggest a positive outlook from the reporting person.

Positives

• The acquisition of shares through the Employee Stock Purchase Plan indicates confidence in the company's future.
• The grant of restricted stock units and stock options aligns Eckert's interests with the long-term success of Xencor Inc.

Future Outlook

The vesting schedules for the restricted stock units and stock options suggest a long-term commitment by the reporting person to the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in Celia Eckert's holdings of Xencor Inc. securities.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of executive compensation in the biotechnology industry, used to align management incentives with shareholder value.
• Vesting schedules of 3-4 years are typical for such grants, similar to practices at companies like Amgen, Regeneron, and Gilead Sciences.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.
• The vesting schedules for stock options and restricted stock units incentivize the reporting person to contribute to the company's long-term success, potentially benefiting shareholders.

Key Dates